ResearchA curated selection of insights from the Maven Bio team.
An analysis of the largest pharma and biotech M&A deals of 2025, examining how Big Pharma deployed capital toward late-stage assets, platform technologies, and durable therapeutic franchises amid rising development costs and approaching patent expiries.
A structured review of U.S. pharma manufacturing and R&D site investments announced in 2025, highlighting where capital was deployed, which companies announced site level expansions or new builds, and how these moves reinforce long term U.S. supply strategies.
Immunology remains the second-largest revenue category in global pharma, with multiple franchises now operating at a scale comparable to Humira at its peak. This report reviews the top-selling immunology drugs in Q3 2025, highlighting how indication expansion, portfolio transitions, and lifecycle management are reshaping competitive dynamics.
An analysis of disease-modifying therapies in type 1 diabetes, covering approved agents and late-stage pipeline programs across immunotherapy, cell therapy, and gene-based approaches reshaping treatment beyond insulin.
A comparative analysis of R&D spending by leading pharmaceutical companies through the first nine months of 2025, highlighting strategic differences in late-stage focus, modality breadth, and post-LOE positioning.
An overview of emerging therapies for Duchenne muscular dystrophy, detailing approved treatments and late-stage pipeline programs across gene therapy, exon-skipping, cell therapy, and small molecules shaping the future of DMD care.
A data-driven review of the top-selling neurology drugs in Q3 2025, highlighting revenue leaders across multiple sclerosis, psychiatry, and movement disorders and their strategic importance to Big Pharma portfolios.
An overview of emerging and newly approved treatments for chronic spontaneous urticaria, detailing targets, clinical status, and how BTK inhibitors, biologics, and novel antibodies are reshaping the CSU treatment landscape.
A structured breakdown of Q3 2025 pharmaceutical revenue by therapeutic area for Novartis, Roche, Sanofi, Bristol Myers Squibb, Novo Nordisk, and Amgen, highlighting portfolio diversification amid upcoming loss of exclusivity.
